Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes

Journal of Clinical Investigation

Volumn 127, Issue 6, 2017, Pages 2133-2147

  Kraakman, Michael J ^a   Lee, Man K S ^a   Al Sharea, Annas ^a   Dragoljevic, Dragana ^a   Barrett, Tessa J ^b   Montenont, Emilie ^b   Basu, Debapriya ^b   Heywood, Sarah ^a   Kammoun, Helene L ^a   Flynn, Michelle ^a   Whillas, Alexandra ^a   Hanssen, Nordin M J ^a,c   Febbraio, Mark A ^d   Westein, Erik ^a   Fisher, Edward A ^b   Chin Dusting, Jaye ^e   Cooper, Mark E ^a   Berger, Jeffrey S ^b   Goldberg, Ira J ^b   Nagareddy, Prabhakara R ^f   Murphy, Andrew J ^a,e   more..

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CALGRANULIN A; CALGRANULIN B; CD11B ANTIGEN; CHOLESTEROL; COGNATE RECEPTOR C MPL; DAPAGLIFLOZIN; HEMOGLOBIN A1C; INTERLEUKIN 6; PADGEM PROTEIN; PAQUINIMOD; RANTES; RECEPTOR; STAT5 PROTEIN; THROMBOPOIETIN; UNCLASSIFIED DRUG; S100A8 PROTEIN, MOUSE; S100A9 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BONE MARROW PROGENITOR CELL; CELL EXPANSION; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETIC PATIENT; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; KUPFFER CELL; LEUKOCYTE ACTIVATION; LIVER CELL; MALE; MEGAKARYOCYTE; MONOCYTE; MOUSE; NEUTROPHIL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RETICULATED THROMBOCYTOSIS; SIGNAL TRANSDUCTION; STEM CELL EXPANSION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS; THROMBOCYTOSIS; ANIMAL; C57BL MOUSE; COMPLICATION; EXPERIMENTAL DIABETES MELLITUS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; THROMBOCYTE;

ANIMALS; ATHEROSCLEROSIS; BLOOD PLATELETS; CALGRANULIN A; CALGRANULIN B; DIABETES MELLITUS, EXPERIMENTAL; HUMANS; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, OBESE; NEUTROPHILS; THROMBOCYTOSIS;

EID: 85020173637     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI92450     Document Type: Article

References (75)

1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229-234.
2. Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care. 2010;33(2):442-449.
3. Shah AD, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol. 2015;3(2):105-113.
4. Lüscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Circulation. 2003;108(13):1655-1661.
5. Pasterkamp G. Methods of accelerated atherosclerosis in diabetic patients. Heart. 2013;99(10):743-749.
6. Nagareddy PR, et al. Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab. 2013;17(5):695-708.
7. Sokunbi DO, Wadhwa NK, Suh H. Vascular disease outcome and thrombocytosis in diabetic and nondiabetic end-stage renal disease patients on peritoneal dialysis. Adv Perit Dial. 1994;10:77-80.
8. Huo Y, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med. 2003;9(1):61-67.
9. Koenen RR, et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med. 2009;15(1):97-103.
10. Murphy AJ, et al. Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis. Nat Med. 2013;19(5):586-594.
11. Martin JF, Kristensen SD, Mathur A, Grove EL, Choudry FA. The causal role of megakaryocyte- platelet hyperactivity in acute coronary syndromes. Nat Rev Cardiol. 2012;9(11):658-670.
12. [No authors listed]. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994;308(6921):81-106.
13. Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care. 2009;32(4):531-540.
14. Guthikonda S, et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol. 2008;52(9):743-749.
15. Neergaard-Petersen S, Hvas AM, Kristensen SD, Grove EL. Platelets and antiplatelet therapy in patients with coronary artery disease and diabetes. Semin Thromb Hemost. 2016;42(3):234-241.
16. Papanas N, et al. Mean platelet volume in patients with type 2 diabetes mellitus. Platelets. 2004;15(8):475-478.
17. Muscari A, et al. Determinants of mean platelet volume (MPV) in an elderly population: relevance of body fat, blood glucose and ischaemic electrocardiographic changes. Thromb Haemost. 2008;99(6):1079-1084.
18. Guthikonda S, et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost. 2007;5(3):490-496.
19. Hekimsoy Z, Payzin B, Ornek T, Kandoǧan G. Mean platelet volume in type 2 diabetic patients. J Diabetes Complicat. 2004;18(3):173-176.
20. Shah B, Valdes V, Nardi MA, Hu L, Schrem E, Berger JS. Mean platelet volume reproducibility and association with platelet activity and anti-platelet therapy. Platelets. 2014;25(3):188-192.
21. Tschoepe D, et al. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost. 1991;17(4):433-438.
22. Vaduganathan M, et al. Platelet reactivity and response to aspirin in subjects with the metabolic syndrome. Am Heart J. 2008;156(5):1002.e1-1002.e7.
23. Karpatkin S. Heterogeneity of human platelets. II. Functional evidence suggestive of young and old platelets. J Clin Invest. 1969;48(6):1083-1087.
24. Kleiman NS. Are immature platelets growing up?: Toward a new marker of antiplatelet drug resistance. J Am Coll Cardiol. 2016;68(3):294-296.
25. Stratz C, et al. Comparison of immature platelet count to established predictors of platelet reactivity during thienopyridine therapy. J Am Coll Cardiol. 2016;68(3):286-293.
26. Junt T, et al. Dynamic visualization of throm-bopoiesis within bone marrow. Science. 2007;317(5845):1767-1770.
27. Schafer AI. Thrombocytosis. N Engl J Med. 2004;350(12):1211-1219.
28. Sungaran R, Markovic B, Chong BH. Localization and regulation of thrombopoietin mRNa expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood. 1997;89(1):101-107.
29. Wolber EM, Fandrey J, Frackowski U, Jelkmann W. Hepatic thrombopoietin mRNA is increased in acute inflammation. Thromb Haemost. 2001;86(6):1421-1424.
30. Kaser A, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood. 2001;98(9):2720-2725.
31. Burmester H, Wolber EM, Freitag P, Fandrey J, Jelkmann W. Thrombopoietin production in wild-type and interleukin-6 knockout mice with acute inflammation. J Interferon Cytokine Res. 2005;25(7):407-413.
32. Gieger C, et al. New gene functions in megakaryopoiesis and platelet formation. Nature. 2011;480(7376):201-208.
33. Koppikar P, et al. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood. 2010;115(14):2919-2927.
34. Pikman Y, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.
35. Eriksson U, Ewald U, Tuvemo T. Increased platelet volume in manifest diabetic rats. Ups J Med Sci. 1983;88(1):17-23.
36. Bacon CM, Tortolani PJ, Shimosaka A, Rees RC, Longo DL, O'Shea JJ. Thrombopoietin (TPO) induces tyrosine phosphorylation and activation of STAT5 and STAT3. FEBS Lett. 1995;370(1-2):63-68.
37. Wong CH, Jenne CN, Petri B, Chrobok NL, Kubes P. Nucleation of platelets with blood-borne pathogens on Kupffer cells precedes other innate immunity and contributes to bacterial clearance. Nat Immunol. 2013;14(8):785-792.
38. Scott CL, et al. Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells. Nat Commun. 2016;7:10321.
39. Klein I, et al. Kupffer cell heterogeneity: functional properties of bone marrow derived and sessile hepatic macrophages. Blood. 2007;110(12):4077-4085.
40. Shah B, Sha D, Xie D, Mohler ER, Berger JS. The relationship between diabetes, metabolic syndrome, and platelet activity as measured by mean platelet volume: the National Health And Nutrition Examination Survey, 1999-2004. Diabetes Care. 2012;35(5):1074-1078.
41. Björk P, et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol. 2009;7(4):e97.
42. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation. 2001;104(13):1533-1537.
43. Hiro T, et al. Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome - serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome Trial (the JAPAN-ACS Trial). Circ J. 2010;74(6):1165-1174.
44. Bayraktar M, Dündar S, Kirazli S, Teletar F. Platelet factor 4, β-thromboglobulin and thrombospondin levels in type I diabetes mellitus patients. J Int Med Res. 1994;22(2):90-94.
45. Roy MS, Podgor MJ, Rick ME. Plasma fibrinopeptide A, beta-thromboglobulin, and platelet factor 4 in diabetic retinopathy. Invest Ophthalmol Vis Sci. 1988;29(6):856-860.
46. Slavka G, et al. Mean platelet volume may represent a predictive parameter for overall vascular mortality and ischemic heart disease. Arterioscler Thromb Vasc Biol. 2011;31(5):1215-1218.
47. Nicolucci A, Standl E. Antiplatelet therapy for every diabetic person? Diabetes Care. 2011;34 Suppl 2:S150-S154.
48. Murphy AJ, et al. Deficiency of ATP-binding cassette transporter B6 in megakaryocyte progenitors accelerates atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2014;34(4):751-758.
49. Murphy AJ, Tall AR. Disordered haematopoiesis and athero-thrombosis. Eur Heart J. 2016;37(14):1113-1121.
50. Maugeri N, et al. Clearance of circulating activated platelets in polycythemia vera and essential thrombocythemia. Blood. 2011;118(12):3359-3366.
51. Grove EL, Hvas AM, Mortensen SB, Larsen SB, Kristensen SD. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost. 2011;9(1):185-191.
52. Stone RL, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366(7):610-618.
53. Jenne CN, Kubes P. Immune surveillance by the liver. Nat Immunol. 2013;14(10):996-1006.
54. Gregory SH, Wing EJ, Danowski KL, van Rooijen N, Dyer KF, Tweardy DJ. IL-6 produced by Kupffer cells induces STAT protein activation in hepatocytes early during the course of systemic listerial infections. J Immunol. 1998;160(12):6056-6061.
55. Kubes P, Mehal WZ. Sterile inflammation in the liver. Gastroenterology. 2012;143(5):1158-1172.
56. Fuentes E, Rojas A, Palomo I. Role of multiligand/ RAGE axis in platelet activation. Thromb Res. 2014;133(3):308-314.
57. Nagareddy PR, et al. Adipose tissue macrophages promote myelopoiesis and monocytosis in obesity. Cell Metab. 2014;19(5):821-835.
58. Croce K, et al. Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation. 2009;120(5):427-436.
59. Wang Y, et al. Platelet-derived S100 family member myeloid-related protein-14 regulates thrombosis. J Clin Invest. 2014;124(5):2160-2171.
60. Dindar S, Cinemre H, Sengul E, Annakkaya AN. Mean platelet volume is associated with glycaemic control and retinopathy in patients with type 2 diabetes mellitus. West Indian Med J. 2013;62(6):519-523.
61. Demirtunc R, Duman D, Basar M, Bilgi M, Teomete M, Garip T. The relationship between glycemic control and platelet activity in type 2 diabetes mellitus. J Diabetes Complicat. 2009;23(2):89-94.
62. Node K, Inoue T. Postprandial hyperglycemia as an etiological factor in vascular failure. Cardiovasc Diabetol. 2009;8:23.
63. Leiter LA, et al. Postprandial glucose regulation: new data and new implications. Clin Ther. 2005;27(suppl B):S42-S56.
64. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes. 2005;54(1):1-7.
65. Cavalot F, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab. 2006;91(3):813-819.
66. Aryangat AV, Gerich JE. Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. Vasc Health Risk Manag. 2010;6:145-155.
67. Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
68. Bengtsson AA, et al. Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo- controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(5):1579-1588.
69. Manitz MP, et al. Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Mol Cell Biol. 2003;23(3):1034-1043.
70. Murphy AJ, et al. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J Clin Invest. 2011;121(10):4138-4149.
71. Tong W, Ibarra YM, Lodish HF. Signals emanating from the membrane proximal region of the thrombopoietin receptor (mpl) support hematopoietic stem cell self-renewal. Exp Hematol. 2007;35(9):1447-1455.
72. Daley JM, Thomay AA, Connolly MD, Reichner JS, Albina JE. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J Leukoc Biol. 2008;83(1):64-70.
73. Renard CB, et al. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest. 2004;114(5):659-668.
74. Shah B, et al. Comparison of platelet activity measurements by use of arterial and venous blood sampling. J Thromb Haemost. 2013;11(10):1922-1924.
75. Michelson AD, Barnard MR, Krueger LA, Frelinger AL, Furman MI. Evaluation of platelet function by flow cytometry. Methods. 2000;21(3):259-270.